Zhong Zheng

US Patent:

20230002738, Jan 5, 2023

Filed:

Feb 24, 2022

Appl. No.:

17/679745

Inventors:

- Oakland CA, US
Kang Ting - Los Angeles CA, US
Zhong Zheng - Van Nuys CA, US

International Classification:

C12N 5/074
A61K 35/12

Abstract:

The present invention provides a method of treating a disorder using a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises administering locally to a human being the FReP cell to a site in need thereof of the human being.

US Patent:

20210401937, Dec 30, 2021

Filed:

Oct 31, 2019

Appl. No.:

17/289664

Inventors:

- Oakland CA, US
Kang TING - Los Angeles CA, US
Zhong ZHENG - Van Nuys CA, US
Chenshuang LI - Van Nuys CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 38/18
A61K 45/06
A61P 19/02

Abstract:

Embodiments of the present invention provide a method treating cartilage arthritis in a subject in need thereof, which method comprising administering an effective amount of NELL-1 protein or peptide to the subject to ameliorate or treat at least an osteoinflammatory cartilage condition in the subject. The present invention also provides a composition and method therefor.

US Patent:

20210128791, May 6, 2021

Filed:

Oct 19, 2020

Appl. No.:

17/073945

Inventors:

- Oakland CA, US
Kang Ting - Los Angeles CA, US
Zhong Zheng - Van Nuys CA, US
Benjamin Wu - San Marino CA, US
Yulong Zhang - Los Angeles CA, US

International Classification:

A61L 27/54
A61L 27/04
A61L 27/06
A61L 31/16
A61L 27/08
A61L 31/02
A61N 1/20

Abstract:

The application discloses an implantable device, comprising a galvanic redox system formed on a body substrate of the implantable device. The implantable device has a non-zero surface potential when it is deployed. The galvanic redox system comprises a first metal site and a second metal site, the first metal site comprising a first metal having a first metal electrode potential (FMEP) and the second metal site comprising a second metal having a second metal electrode potential (SMEP), which FMEP being lower than SMEP and SMEP being substantially different such that the implantable device is galvanized when it is deployed. Methods of making and using the implantabe device are also disclosed.

US Patent:

20200345811, Nov 5, 2020

Filed:

Jul 14, 2020

Appl. No.:

16/928724

Inventors:

- Oakland CA, US
Kang Ting - Los Angeles CA, US
Zhong Zheng - Van Nuys CA, US

International Classification:

A61K 38/18
A61K 38/17

Abstract:

The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.

US Patent:

20200270311, Aug 27, 2020

Filed:

May 8, 2020

Appl. No.:

16/870648

Inventors:

- Memphis TN, US
Ying Zhao - Memphis TN, US
Elizabeth Griffith - Germantown TN, US
Zhong Zheng - Irvine CA, US
Aman P. Singh - Memphis TN, US

International Classification:

C07K 11/02
A61K 38/15
A61K 45/06
C12N 9/50
C07K 7/06

Abstract:

In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

US Patent:

20180127469, May 10, 2018

Filed:

Jan 5, 2018

Appl. No.:

15/863673

Inventors:

- Memphis TN, US
Ying Zhao - Memphis TN, US
Elizabeth Griffith - Germantown TN, US
Zhong Zheng - Irvine CA, US
Aman P. Singh - Memphis TN, US

International Classification:

C07K 11/02
C07K 7/06
A61K 38/15
C12N 9/50
A61K 45/06
A61K 38/00

Abstract:

In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

US Patent:

20160347762, Dec 1, 2016

Filed:

Sep 29, 2014

Appl. No.:

15/024549

Inventors:

- Memphis TN, US
Samanthi L. Waidyarachchi - Southaven MS, US
David F. Bruhn - Memphis TN, US
Zhong Zheng - Irvine CA, US
Jason W. Rosch - Memphis TN, US

Assignee:

ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. - Memphis TN

International Classification:

C07D 493/04
A61K 45/06
A61K 9/00
A61K 31/4433
A61K 31/381
A61K 31/497
A61K 31/4178
A61K 31/428
A61K 31/4045
A61K 31/4025
A61K 31/5377
A61K 31/357
A61K 31/427

Abstract:

The invention relates to aryl substituted aminomethyl spectinomycin analogs, derivatives thereof, and related compounds, which are useful as anti-bacterial agents; methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating anti-bacterial infections using the compounds and compositions.

US Patent:

20160200770, Jul 14, 2016

Filed:

Aug 30, 2014

Appl. No.:

14/914449

Inventors:

- Memphis TN, US
Ying Zhao - Memphis TN, US
Elizabeth Griffith - Germantown TN, US
Zhong Zheng - Irvine CA, US
Aman P. Singh - Memphis TN, US

International Classification:

C07K 11/02
A61K 45/06
C12N 9/50
A61K 38/15

Abstract:

In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.